Skip to main content

Table 2 Patient characteristics

From: Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis

Characteristics n (%)
Age, y
 ≥ 50 48 (68.6)
 < 50 22 (31.4)
Gender
 Male 59 (84.3)
 Female 11 (15.7)
Therapeutic modalities
 SBRT alone 20 (28.6)
 SBRT+TACE 46 (65.7)
 SBRT+Surgery 4 (5.7)
Dose, Gy
 ≤ 35.0 29 (41.4)
 ≥ 40.0 41 (58.6)
Types of PVTT
 II 42 (60.0)
 III 27 (38.6)
 IV 1 (1.4)
HBsAg
 Negative 12 (17.1)
 Positive 58 (82.9)
Child-Pugh classification
 A 45 (64.3)
 B 24 (34.3)
 C 1 (1.4)
PS (ECOG)
 0 56 (80.0)
 1 14 (20.0)
Origination of PVTT
 Right branch 49 (70.0)
 Left branch 21 (30.0)
AFP, ng/L
 ≤ 20 13 (18.6)
 21 ~ 399 17 (24.3)
 ≥ 400 40 (57.1)
PLT, 109/L
 ≥ 100 39 (55.7)
 < 100 31 (44.3)
HGB, g/L
 ≥ 120 42 (60.0)
 < 120 28 (40.0)
TBIL, μmol/L
 ≥ 20 34 (48.6)
 < 20 36 (51.4)
Albumin, g/L
 ≥ 35 41 (58.6)
 < 35 29 (41.4)
ALT, U/L
 ≥ 50 25 (35.7)
 < 50 45 (64.3)
AST, U/L
 ≥ 50 48 (68.6)
 < 50 22 (31.4)
  1. Abbreviations: SBRT Stereotactic body radiotherapy, Types types of tumor thrombi, HBsAg Hepatitis B surface antigen, PS Performance status, ECOG Eastern Cooperative Oncology Group, AFP Alpha–fetoprotein, PLT Platelet, HGB Hemoglobin, TBIL Total bilirubin, ALT Alanine aminotransferase, AST Aspartate aminotransferase